DexCom earnings beat by $0.03, revenue topped estimates
Vivani Medical (TASE:BLWV), Inc. (NASDAQ:VANI) director and significant shareholder Gregg Williams has recently acquired additional shares of the company’s common stock. According to a recent SEC filing, Williams purchased 1,113 shares on April 24, 2025, at a price of $1.01 per share, totaling approximately $1,124. The purchase comes as InvestingPro data shows the stock trading at $1.05, near its 52-week low of $0.91, with analysts setting an optimistic target of $4.00.
Following this transaction, Williams holds a significant stake in Vivani Medical, with a total of 13,828,155 shares owned indirectly through various trusts and investment entities. This acquisition adds to his already substantial holdings in the $62 million market cap company, demonstrating continued confidence despite InvestingPro analysis indicating rapid cash burn and volatile stock performance. Subscribers to InvestingPro can access 7 additional key insights about VANI’s financial health and market position.
In other recent news, Vivani Medical reported a net loss of $23.5 million for 2024, aligning closely with H.C. Wainwright’s expectations. The company has also expanded its partnership with Okava Pharmaceuticals to develop a long-acting therapy for dogs using its NanoPortal technology. Vivani Medical successfully completed enrollment for its Phase 1 LIBERATE-1 trial of the exenatide implant NPM-115, with results anticipated by mid-2025. Analyst Yi Chen from H.C. Wainwright maintained a Buy rating for Vivani Medical, reaffirming a $4 price target. The company secured $8.25 million through a private placement to support the development of its semaglutide implant NPM-139, aimed at chronic weight management. Recent preclinical studies showed NPM-139 achieved significant weight loss in rats, with potential for annual dosing. Vivani Medical’s NanoPortal technology underpins both NPM-115 and NPM-139, offering extended medication delivery to improve adherence. The company is leveraging Australian R&D rebates for its clinical trials, with data expected to meet FDA standards. These developments reflect Vivani Medical’s strategic efforts to advance its product pipeline and strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.